Skip to content
ANAVEX
ANAVEX
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
  • JOIN US
Search
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
  • JOIN US
View allAlzheimer's DiseaseAnavex2-73EventsNews ReleasesPDDPIPELINEPressRett Syndrome

New Exploratory Alzheimer’s Drug ANAVEX 2-73: Assessment of Safety and Cognitive Performance in a Phase 2a Study in mild-to-moderate Alzheimer’s Patients.

November 27, 2015

Anavex Announces Executive Overseeing Regulatory Affairs

November 25, 2015

Anavex to Present at American Epilepsy Society Annual Meeting ANAVEX 2-73 Demonstrates Anti-Seizure Effects in Well Established Preclinical Seizure Models

November 19, 2015

Anavex Announces Preparation of Regulatory Filings based on Guidance From the FDA

November 18, 2015

New Exploratory Alzheimer’s Drug ANAVEX 2-73 Changes in Electrophysiological Markers in Alzheimer’s Disease – First Patient Data from an ongoing Phase 2a Study in mild-to-moderate Alzheimer’s Patients.

November 11, 2015

Anavex Confirms Data for Phase 2a Alzheimer’s Trial for ANAVEX 2-73

November 11, 2015

Anavex Announces Positive Primary and Secondary Endpoints were Achieved in a Phase 2a Clinical Trial of ANAVEX 2-73 in Alzheimer’s Disease‎

November 9, 2015

Anavex Announces CTAD 2015 Abstract

November 5, 2015

Anavex Commences Trading on NASDAQ Today – To Ring Friday’s Closing Bell

October 28, 2015

Anavex Announces Uplisting to NASDAQ

October 26, 2015

Anavex to Present at 4th Annual OktoberINVESTfest Conference

October 12, 2015

Anavex to Present Interim Phase 2a Clinical Trial Data of ANAVEX 2-73 at Late-Breaking Oral Session of CTAD 2015 Conference

October 7, 2015
1
23456789101112131415
…1617181920…
21222324252627282930313233343536373839404142
43

ANAVEX® is a trademark of Anavex®Life Sciences Corp. - 2019 All Rights Reserved

Go to Top